Cynata Therapeutics posts FY2026 after-tax loss of A$9.1 million
Cynata Therapeutics reported a FY2026 loss from ordinary activities after tax of A$9.1 million.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.